Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.
Ovarian Cancer
DRUG: paclitaxel|DRUG: pazopanib
progression free survival, 6 months from randomization
number of patients with objective response, at 2 months and 4 months after randomization|worst grade toxicity per patient, at end of each 28 day cycle of therapy|overall survival, one year from randomization
The purpose of this study is to evaluate the safety and activity of adding pazopanib to weekly chemotherapy with paclitaxel for patients with ovarian cancer that is resistant or refractory to treatment with platinum based therapy.